Moderate marijuana use may tamp risk of H&N cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 11
Volume 18
Issue 11

Cannabinoids, which are a byproduct of marijuana smoke, have been recognized to have potential antitumor properties, but evidence of a relationship between marijuana use and the induction of head and neck squamous cell carcinoma has been inconsistent.

Cannabinoids, which are a byproduct of marijuana smoke, have been recognized to have potential antitumor properties, but evidence of a relationship between marijuana use and the induction of head and neck squamous cell carcinoma has been inconsistent.

Researchers from Brown University in Providence, RI, set out to clear up some of the conflicting evidence and found an attenuated risk of HNSCC among those who used marijuana compared with those who did not.

The investigators in the department of community health compiled data on 434 cases of incident HNSCC disease from nine medical facilities in the greater Boston area over a four-year period. A control group (547 people) was matched to the study population based on age, gender, and town of residence.

A questionnaire was used to collect information on lifetime marijuana use (decade-specific exposures); the associations were evaluated using unconditional logistic regression. The authors found that after adjusting for potential confounders (nicotine smoking, alcohol drinking), 10 to 20 years of marijuana use was associated with a significantly reduced risk of HNSCC (odds ratio [OR] = 0.38 for 10 to < 20 years vs never users).

Among marijuana users, moderate weekly use was associated with reduced risk (OR = 0.52 for 0.5 to < 1.5 times vs < 0.5 time). The magnitude of reduced risk was more pronounced for those who started use at an older age, the authors noted. These inverse associations did not depend on HPV16 antibody status (Cancer Prev Res 2:759-768, 2009).

For those subjects who have the same level of smoking or alcohol drinking, there was an attenuated risk of head and neck carcinoma among marijuana users vs those who did not use marijuana, the authors reported.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Related Content